Abstract
Background:
Measurement of 17-hydroxyprogesterone (17-OHP) in dried blood spots has been widely used as a newborn screening tool for congenital adrenal hyperplasia (CAH). Various maternal and neonatal factors can result in falsely high values of 17-OHP. There is a paucity of Indian studies in this regard because routine evaluation of newborn 17-OHP levels as a screening program is not widely practiced in India. Hence, this study was undertaken to evaluate the influence of various maternal and neonatal factors on newborn 17-OHP levels. The aim of the study was to determine the effect of various maternal and neonatal factors on the newborn 17-OHP values.
Methods:
Retrospective data related to a total of 3080 newborn 17-OHP values and clinical characteristics were collected for 3 years (2013–2015). The data were analyzed to determine the influence of various factors on 17-OHP values.
Results:
The mean value of 17-OHP in our study was 5.486±3.96 ng/mL. Gender and mode of delivery did not significantly affect the 17-OHP levels. The levels were significantly higher in preterm and low birth weight babies as compared to term babies and babies with normal birth weight. Stress factors like pregnancy induced hypertension (PIH), early onset sepsis (EOS), neonatal seizures and birth asphyxia significantly increase the neonatal 17-OHP levels.
Conclusions:
The levels of 17-OHP in newborns was measured around day 3 of life are very sensitive to the influence of gestational age, birth weight and presence of stress factors like maternal PIH, birth asphyxia, neonatal sepsis and neonatal seizures and should be interpreted cautiously.
Author contributions: Dr. V. Shobi Anandi and Dr. Shaila Bhattacharya were involved in conceptualization of the manuscript, collecting patient data, conducting literature search and drafting the manuscript. Dr. Shaila Bhattacharya supervised the data collection helped in literature search and revised the manuscript for scientific content. Both the authors were involved in clinical management of the patient. Dr. Shaila Bhattacharya will act as the guarantor of the paper. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Chennuri VS, Mithbawkar SM, Mokal RA, Desai MP. Serum 17 alpha hydroxyprogesterone in normal full term and preterm vs sick preterm and full term newborns in a tertiary hospital. Indian J Pediatr 2013;80:21–5.10.1007/s12098-012-0856-zSearch in Google Scholar PubMed
2. Barra CB, Silva IN, Pezzuti IL, Januario JN. Neonatal screening for congenital adrenal hyperplasia. Rev Assoc Med Bras (1992) 2012;58:459–64.10.1590/S0104-42302012000400017Search in Google Scholar
3. Zhang Q, Wang B, Chen Y, Jiang D. [Multicenter investigation on the impact of newborn infants’ gestational age and birth weight on the level of 17alpha-hydroxyprogesterone]. Zhonghua er ke za zhi 2014;52:706–9.Search in Google Scholar
4. al-Nuaim AR, Abdullah MA, Stevens B, Zain M. Effect of gender, birth weight and gestational age on serum 17-hydroxyprogesterone concentration and distribution among neonates in Saudi Arabia. Indian J Pediatr 1995;62:605–9.10.1007/BF02761890Search in Google Scholar PubMed
5. Ryckman KK, Cook DE, Berberich SL, Shchelochkov OA, Berends SK, et al. Replication of clinical associations with 17-hydroxyprogesterone in preterm newborns. J Pediatr Endocrinol Metab 2012;25:301–5.10.1515/jpem-2011-0456Search in Google Scholar PubMed PubMed Central
6. van der Kamp HJ, Oudshoorn CG, Elvers BH, van Baarle M, Otten BJ, et al. Cutoff levels of 17-α-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab 2005;90:3904–7.10.1210/jc.2004-2136Search in Google Scholar PubMed
7. Pauwels G, Allegaert K, Regal L, Meulemans A. Risk factors for elevated levels of 17-hydroxyprogesterone during neonatal intensive care unit admission. Acta Clinica Belgica 2012;67: 88–93.Search in Google Scholar
8. Gatelais F, Berthelot J, Beringue F, Descamps P, Bonneau D, et al. Effect of single and multiple courses of prenatal corticosteroids on 17-hydroxyprogesterone levels: implication for neonatal screening of congenital adrenal hyperplasia. Pediatr Res 2004;56:701–5.10.1203/01.PDR.0000142733.50918.6ESearch in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston
